ELAA Technology and Clionix has started a collaboration for the exclusive sales and distribution of ELAA Technology products in the regions that Clionix is active.
The deal includes all products that is developed by ELAA Technology in Azerbaijan, Bulgaria, Georgia and Romania thanks its proprietary Pure Digital Medical Navigation Technology and it will start with PRECIMON, Pure Digital Lung Navigation System, which is a Class-II medical device to be used in conjunction with a bronchoscope for early diagnosis of lung cancer.
“This is our first international business development agreement and we are excited to partner with Clionix, a leader in oncology and niche products. We believe our Pure Digital Medical Navigation Platform will enable rapid patient diagnosis and reduce the burden of healthcare expenditures of health systems”. commented Dr.Tunç Laçin, co-founder and Chief Scientific Officer of ELAA Technology.
“We believe this addition to our portfolio will strengthen our position in oncology field and we hope to serve the community in our region in a better way to meet their needs in early diagnosis of certain cancer types.”, said Hasan Ulaş Özcan, managing director of Clionix.
About ELAA Technology :
ELAA Technology is a digital health company focusing on cancer early diagnosis. ELAA Technology’s patent pending Pure Digital Medical Navigation Platform has been the basis for development of new products for cancer early diagnosis market.
About Clionix :
Clionix is a next generation oncology diagnostics company currently commercializing multiple products and operating in CEE region.